EUVIMEDEUVIMED entdecken
Crossref

Clinical Long-term Sedation Profiles of Remimazolam Compared with Propofol for Gastric Endoscopic Submucosal Dissection: Prospective, Single-Center Pilot Study

H. J. Jeon, J. C. Hoon, B. Lee, Y. Jiyoung, S. Kim, S. C. Hyuk, S. K. Eun, B. Keum, T. J. Yoon

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S190-S191

DOI: 10.1055/s-0044-1783119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von H. J. Jeon und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Remimazolam is a short-acting benzodiazepine approved by the US Food and Drug Administration (FDA) for procedural sedation. Remimazolam now has been utilized to sedate adults during invasive medical procedures, such as gastrointestinal endoscopy and bronchoscopy. This study aims to compare the efficacy and safety of remimazolam with propofol during gastric endoscopic submucosal dissection.

Methods

This study was conducted as a single-center pilot study at Korea University Medical Center. A total of 40 patients were enrolled and randomized. The primary endpoint was safety, assessed by the incidence of hypotension and respiratory depression. Secondary endpoints included the dose of sedatives administered and sedative satisfaction. Remimazolam was titrated from an initial bolus of 5 ml to achieve target sedation, with vital signs monitored at 5-minute intervals throughout the procedure.

Results

The mean procedure times in each group were 29.5±8.4 (min) and 32.8±5.9 (min), respectively. The sedative doses used during the procedure were 12.5 ml and 21.8 ml. Hypotension was observed in 2 (10%) and 4 (20%) patients in the remimazolam and propofol groups, respectively. Respiratory depression was observed in 3 patients (15%) in the remimazolam group and 4 patients (20%) in the propofol group, with no statistical difference between the two. There was no difference in overall sedation-related satisfaction between the two groups, with scores of 8.5 and 8.8, respectively.

Conclusions

Remimazolam exhibited a satisfactory sedation profile compared to propofol, and it appears that further comparison with a larger patient cohort will be necessary in the future. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Jeon, H. J., Hoon, J. C., Lee, B., Jiyoung, Y., Kim, S., Hyuk, S. C., Eun, S. K., Keum, B., & Yoon, T. J. (2024). Clinical Long-term Sedation Profiles of Remimazolam Compared with Propofol for Gastric Endoscopic Submucosal Dissection: Prospective, Single-Center Pilot Study. Endoscopy, 56(S 02 S 02), S190-S191. https://doi.org/10.1055/s-0044-1783119

Vancouver

Jeon HJ, Hoon JC, Lee B, Jiyoung Y, Kim S, Hyuk SC, et al. Clinical Long-term Sedation Profiles of Remimazolam Compared with Propofol for Gastric Endoscopic Submucosal Dissection: Prospective, Single-Center Pilot Study. Endoscopy. 2024;56(S 02 S 02):S190-S191. doi:10.1055/s-0044-1783119

BibTeX
@article{Jeon2024,
  author = {Jeon, H. J. and Hoon, J. C. and Lee, B. and Jiyoung, Y. and Kim, S. and Hyuk, S. C. and Eun, S. K. and Keum, B. and Yoon, T. J.},
  title = {Clinical Long-term Sedation Profiles of Remimazolam Compared with Propofol for Gastric Endoscopic Submucosal Dissection: Prospective, Single-Center Pilot Study},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S190--S191},
  doi = {10.1055/s-0044-1783119}
}
Kostenlos starten →